Cited by 417RNA Interference and Gene DeliveryDNA and Nucleic Acid ChemistryRNA Research and Splicing

The DOI matches its Crossref record; 241 of the 243 references it cites were found in a registry or an index.

Progress in Antisense Technology

Crooke, Stanley T.·2004·Annual Review of Medicine

DOI 10.1146/annurev.med.55.091902.104408

Open this paper in CoChat — free account

Abstract

Antisense technology exploits oligonucleotide analogs to bind to target RNAs via Watson-Crick hybridization. Once bound, the antisense agent either disables or induces the degradation of the target RNA. Antisense agents can also alter splicing. During the past decade, much has been learned about the basic mechanisms of antisense, the medicinal chemistry, and the pharmacologic, pharmacokinetic, and toxicologic properties of antisense molecules. Antisense technology has proven valuable in gene functionalization and target validation. With one drug marketed, Vitravenetm, and approximately 20 antisense drugs in clinical development, it appears that antisense drugs may prove important in the treatment of a wide range of diseases.

Integrity signals

Registry

Crossref · 10.1146/annurev.med.55.091902.104408

Cites

241 of 241 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
RNAi
Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,751
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Predicting DNA duplex stability from the base sequence
Breslauer, K. J., Frank, R., Blöcker, H., & Marky, L. A. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.3746 · Cited by 1,837
Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Functional genomic analysis of C. elegans chromosome I by systematic RNA interference
Fraser, A. G., Kamath, R. S., Zipperlen, P., Martinez-Campos, M., Sohrmann, M., & Ahringer, J. (2000) · Nature · doi:10.1038/35042517 · Cited by 1,761
Anti-cancer Drug Design
SISSAOUI, M. (2018) · Archives of Clinical Microbiology · doi:10.4172/1989-8436-c3-011 · Cited by 1,352
Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
Stein, C., & Cheng, Y. C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,300
Morpholino Antisense Oligomers: Design, Preparation, and Properties
Summerton, J. E., & Weller, D. D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,137

Show all 243 references

Research works printed but not linked: 39

Crouch RJ, 1985, Nucleases, 211
Morvan F, 1991, Anticancer Drug Des., 6, 521
Mirabelli CK, 1991, Anti-Cancer Drug Design, 6, 647
42. Cohen JS. 1993. Phosphorothioate oligodeoxynucleotides. See Ref.42a, pp.205–22
Crooke ST, 1996, J. Pharmacol. Exp. Ther., 277, 923
Joos RW, 1969, J. Pharmacol. Exp. Ther., 166, 113
Crooke RM, 1995, J. Pharmacol. Exp. Ther., 275, 462
Gao W-Y, 1992, Mol. Pharmacol., 41, 223
Stein CA, 1991, J. Acquired Immune Deficiency Syndromes, 4, 686
Cossum PA, 1993, J. Pharmacol. Exp. Ther., 267, 1181
Crooke ST, 1993, Curr. Opin. Invest. Drugs, 2, 1045
Sands H, 1995, Mol. Pharmacol., 47, 636
Crooke RM, 1991, Anti-Cancer Drug Design, 6, 609
67. Crooke RM. 1993. in vitro and in vivo toxicology of first generation analogs. See Ref.42a, pp.471–92
Bennett CF, 1992, Mol. Pharmacol., 41, 1023
Iversen P, 1992, Anticancer Drug Des., 6, 531
Cossum PA, 1994, J. Pharmacol. Exp. Ther., 269, 89
10.1038/clpt.1994.189 · DOI
Butler M, 1997, Lab. Invest., 77, 379
Sands H, 1994, Mol. Pharmacol., 45, 932
Graham MJ, 1998, J. Pharmacol. Exp. Ther., 286, 447
95. Mirabelli CK, Crooke ST. 1993. Antisense oligonucleotides in the context of modern molecular drug discovery and development. See Ref.42a, pp.7–35
103. Crooke ST, Mirabelli CK. 1993. Antisense oligonucleotides in the context of modern molecular drug discovery and development. See Ref.42a, pp.7–35
Zhang S-P, 1994, J. Pharmacol. Exp. Ther., 271, 1462
Dean N, 1996, Cancer Res., 56, 3499
Maksymowych W, 1999, Arthritis Rheumatol., 42, S170
O'Dwyer PJ, 1999, Clin. Cancer Res., 5, 3977
Henry SP, 1997, J. Pharmacol. Exp. Ther., 281, 810
Cornish KG, 1993, Pharmacol.Comm., 3, 239
Henry SP, 1997, Anti-Cancer Drug Des., 12, 395
Wallace TL, 1996, J. Pharmacol. Exp. Ther., 278, 1306
Henry S, 1994, Pharm. Res., 11, S-353/S1-S490
Lemonidis-Farrar K, 2000, Toxicologist, 42, 120
Yuen AR, 1999, Clin. Cancer Res., 5, 3357
164. Crooke ST. 2001. Basic principles. See Ref.46a, pp.1–28
Zellweger T, 2001, J. Pharmacol. Exp. Ther., 298, 1
Geary RS, 2001, J. Pharmacol. Exp. Ther., 296, 898
Geary RS, 2001, J. Pharmacol. Exp. Ther., 296, 890
Henry SP, 2000, J. Pharmacol. Exp. Ther., 292, 468

Sorted by citations

Items 301–400 of 417

Design and Synthesis of LNA-Based Mercaptoacetamido-Linked Nucleoside Dimers
Sharma, V. K., Singh, S. K., Bohra, K., Chandra Shekhar Reddy, L., Khatri, V., Olsen, C. E., & Prasad, A. K. (2013) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2013.783218 · Cited by 7
Antisense approaches to immune modulation for transplant and autoimmune diseases
Mourich, D. V., & MARSHALL, N. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.018 · Cited by 7
CD40 and tolerance induction.
Karimi, M. H., & Pourfathollah, A. A. (2012) · PubMed · Cited by 7
Synthesis and Gene Silencing Properties of siRNAs Containing Terminal Amide Linkages
Gaglione, M., Mercurio, M. E., Potenza, N., Mosca, N., Russo, A., Novellino, E., Cosconati, S., & Messere, A. (2014) · BioMed Research International · doi:10.1155/2014/901617 · Cited by 7
Antisense Apolipoprotein B-100 As Novel Treatment For Hypercholesterolemia: Focus On Isis 301012
Akdim, F., Harchaoui, K. E., Stroes, E. S. G., & Kastelein, J. J. P. (2007) · Future Lipidology · doi:10.2217/17460875.2.4.387 · Cited by 7
“These compounds have greater potency, longer half-life and a reduced potential for nonspecific side effects [14,15].”
Background
Consequences of P‐Chirality in Chimeric 2′‐O‐Methyloligoribonucleotides with Stereoregular Methylphosphonothioate Linkages
Woźniak, L. A., Janicka, M., & Bukowiecka‐Matusiak, M. (2005) · European Journal of Organic Chemistry · doi:10.1002/ejoc.200500395 · Cited by 7
Targeting ApoB as a therapeutic approach for the treatment of dyslipidemia: the potential role of mipomersen
Thomas, T. A., & Ginsberg, H. N. (2010) · Clinical Lipidology · doi:10.2217/clp.10.47 · Cited by 7
The 5-Me of thyminyl (T) interaction with the neighboring nucleobases dictate the relative stability of isosequential DNA–RNA hybrid duplexes
Chatterjee, S., Pathmasiri, W., & CHATTOPADHYAYA, J. B. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b511139k · Cited by 7
Antisense Therapeutics: A Promise Waiting to Be Fulfilled
Phillips, M. I. (2004) · Humana Press eBooks · doi:10.1385/1-59259-854-4:003 · Cited by 7
Strategies to Identify Potential Therapeutic Target Sites in RNA
Lützelberger, M., & Kjems, J. (2006) · Springer eBooks · doi:10.1007/3-540-27262-3_12 · Cited by 7
“To date only one antisense drug, Vitravene (Isis Pharmaceuticals, Carlsbad, CA, USA), which targets the cytomegalovirus IE2 mRNA, has been approved by the Food and Drug Administration (FDA), and approximately 20 are in clinical trials ( Crooke 2004 ).”
Background
Oligonucleotide Based Artificial Ribonucleases (OBANs)
Ghidini, A., Murtola, M., & Strömberg, R. (2014) · doi:10.1002/9781118696880.ch3.2 · Cited by 7
Recent Advances in Ocular Nucleic Acid-Based Therapies: The Silent Era
Paeda, C., Martnez, T., Wright, N., & Isabel, A. (2012) · InTech eBooks · doi:10.5772/48454 · Cited by 7
“Around 50 clinical studies have used antisense strategies spanning a variety of disease processes, including cancer, cardiovascular disease, inflammation and infection (10).”
Background
The shaping of a molecular linguist: How a career studying DNA energetics revealed the language of molecular communication
Breslauer, K. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100522 · Cited by 6
Stereochemistry of internucleotide bond formation by the H-phosphonate method. Part 6: Optimization of the reaction conditions towards highest stereoselectivity
Sobkowski, M., Stawiński, J., & Kraszewski, A. (2008) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2008.11.002 · Cited by 6
Small‐Molecule‐Mediated Cleavage of RNA in Living Cells
Guan, L., & Disney, M. D. (2012) · Angewandte Chemie · doi:10.1002/ange.201206888 · Cited by 5
An RNA modification with remarkable resistance to RNase A
Ghidini, A., Ander, C., Winqvist, A., & Strömberg, R. (2013) · Chemical Communications · doi:10.1039/c3cc44621b · Cited by 5
ODN 491, a Novel Antisense Oligodeoxynucleotide That Targets Thymidylate Synthase, Exerts Cell-Specific Effects in Human Tumor Cell Lines
Jason, T. L. H., Figueredo, R., Ferguson, P. J., Vincent, M. D., Berg, R. W., & Koropatnick, J. D. (2008) · DNA and Cell Biology · doi:10.1089/dna.2007.0674 · Cited by 5
“In vitro reports and pharmacokinetic and toxicology studies of AS ODNs in animals and in humans, on the other hand, have conﬁrmed their safety and potential therapeutic usefulness (Berg, et al. , 2002; Holmlund 2003; Crooke, 2004; Jason et al. , 2004).”
Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?
Volta, A., Hovingh, G. K., & Grefhorst, A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000489 · Cited by 5
“Mipomersen is a synthetic antisense oligonucleotide that binds APOB mRNA via complementary sequence interactions [20] resulting in reduced apolipoprotein B synthesis.”
Background
Getting a handle on Huntington's disease: silencing neurodegeneration
Spada, A. R. L. (2009) · Nature Medicine · doi:10.1038/nm0309-252 · Cited by 5
Antisense regulation of expression and transactivation functions of the tumorigenic HBx and c-myc genes
Hung, L., & Kumar, V. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.103 · Cited by 5
“Our cell culture-based study appears equally promising and need to be validated further in vivo like some new anti-neoplastic ASOs [33,34].”
Background
NMR studies of the conformational effect of single and double 3′‐S‐phosphorothiolate substitutions within deoxythymidine trinucleotides
Jayakumar, H. K., Buckingham, J., Brazier, J. A., Berry, N. G., Cosstick, R., & Fisher, J. (2007) · Magnetic Resonance in Chemistry · doi:10.1002/mrc.1977 · Cited by 5
Imaging and Modulating Antisense Microdistribution in Solid Human Xenograft Tumor Models
Mocanu, J. D., Yip, K. W., Skliarenko, J., Shi, W., Busson, P., Lo, K. W., Bastianutto, C., & Liu, F. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3085 · Cited by 5
Oligonucleotide Analogs with Peptide Internucleotide Linkages
Varizhuk, A. M., Kochetkova, S. V., Kolganova, N. A., Timofeev, E. N., & Florentiev, V. L. (2011) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2010.542790 · Cited by 5
The Internalization Mechanisms and Bioactivity of the Cell‐Penetrating Peptides
Hansen, M., Eriste, E., & Langel, Ü. (2009) · doi:10.1002/9783527626830.ch7 · Cited by 5
Identification of Structural Motif of RNAs Interacting with the G-rich Sequence RNA
Cho, B. (2012) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2012.33.8.2796 · Cited by 4
Probabilistic Neural Network Inferences on Oligonucleotide Classification Based on Oligo: Target Interaction
Anusha, A. R., & S, V. C. S. (2017) · Lecture notes in computer science · doi:10.1007/978-3-319-54430-4_70 · Cited by 4
Evaluation of Pharmacokinetics and Metabolism of Phosphorothioate Antisense Oligonucleotide G3139 in Rat by Capillary Electrophoresis with Laser-Induced Fluorescence
Ban, E., Kwon, H., & Song, E. J. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0922 · Cited by 4
Bypassing Bypass Surgery and Other Success Stories from the National Institutes of Health.
Nijhara, R., Jl, T., Ferguson, S., & Balakrishnan, K. (2005) · PubMed · Cited by 4
Who Colonises Whom? Educational Technologies or Societal Cultures
Borovoi, L., Foland, J. R., & Vlaev, I. (2016) · Science Technology and Society · doi:10.1177/0971721816640624 · Cited by 4
Inhaled antisense oligonucleotide therapies: Inspiration and progress
Karras, J. G., Geary, R. S., & Gregory, S. A. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.08.002 · Cited by 4
Effects of acid-mediated deamination of cytidine and 5-methylcytidine on solid-phase synthesis of oligonucleotides
Isono, Y., Karasugi, C., Akisawa, T., Osawa, T., Ren, Q., Tatsuno, M., Ito, F., Inoué, T., Kawakami, J., Obika, S., et al. (2025) · Tetrahedron · doi:10.1016/j.tet.2025.134840 · Cited by 3
Probing the Effects of Chemical Modifications on Anticoagulant and Antiproliferative Activity of Thrombin Binding Aptamer
Virgilio, A., Benigno, D., Aliberti, C., Bello, I., Panza, E., Smimmo, M., Vellecco, V., Esposito, V., & Galeone, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010134 · Cited by 3
2′-Deoxy-5-propynyluridine: a nucleoside with two conformations in the asymmetric unit
Budow, S., Eickmeier, H., Reuter, H., & Seela, F. (2009) · Acta Crystallographica Section C Crystal Structure Communications · doi:10.1107/s0108270109044850 · Cited by 3
“This makes them useful for the development of polymer therapeutics by antisense or antigene technology with the aim of gene silencing (Manoharan, 2004; Praseuth et al., 1999; Crooke, 2004).”
Background
Design and Synthesis of Some New α‐Phenyl Cinnamoyl Derivatives for Selective Protection of Purine Nucleosides
Tripathi, S., Misra, K., & Sanghvi, Y. S. (2005) · Synthetic Communications · doi:10.1080/00397910500278867 · Cited by 3
Stability of a 2′‐O‐(Carbamoylmethyl)adenosine‐Containing Dinucleotide
Milton, S., Ander, C., Yeheskiely, E., & Strömberg, R. (2011) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201101264 · Cited by 3
Identification of Structural Motifs of RNA Aptamers Interacting with the Stem-loop Sequence at the Gag-pol Junction of HIV-1 RNA
Shin, E. (2008) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2008.29.11.2227 · Cited by 3
Suppression of Hepatitis C Viral Genome Replication with RNA-Cleaving Deoxyribozyme
Min, D., & Kim, D. (2012) · RNA technologies · doi:10.1007/978-3-642-27426-8_17 · Cited by 3
“If AS-ODNs that were sensitive to nuclease degradation were used without appropriate delivery vehicle, low-affinity profiles toward their target and side effects were often observed in vivo (Crooke 2004).”
Background
Formes galéniques nouvelles en cancérologie
Astier, A. (2006) · Annales Pharmaceutiques Françaises · doi:10.1016/s0003-4509(06)75290-7 · Cited by 3
Antisense Oligonucleotides: Insights from Preclinical Studies and Clinical Trials
Kunze, D., Kraemer, K., & Fuessel, S. (2010) · RNA technologies · doi:10.1007/978-3-642-12168-5_13 · Cited by 3
Neurodegeneration and Ageing: A Fatal Encounter
Chanu, S. I., Singh, M. D., Yadav, R., Raj, K., & Sarkar, S. (2013) · Cell & Developmental Biology · doi:10.4172/2168-9296.s1-002 · Cited by 2
“AONs are synthetic short antisense 15-25 long oligonucleotides that bind to target in a sequence specific manner and silence the mRNAs either via RNAse H facilitated degradation or by blocking translation through steric hindrance posed to translational machinery [115,116,117].”
Background
How RNase HI ( Escherichia coli ) promoted site-selective hydrolysis works on RNA in duplex with carba-LNA and LNA substituted antisense strands in an antisense strategy context?
Plashkevych, O., Li, Q., & CHATTOPADHYAYA, J. B. (2017) · Molecular BioSystems · doi:10.1039/c6mb00762g · Cited by 2
Antisense locked nucleic acid gapmers to control Candida albicans filamentation
Araújo, D., Mil‐Homens, D., Rodrigues, M. E., Henriques, M., Jørgensen, P. T., Wengel, J., & Silva, S. M. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102469 · Cited by 2
TGF-β Targeted by miR-27a Modulates Anti-Parasite Responses of Immune System
Hamidi, F., Mohammadi‐Yeganeh, S., Hoseini, M. H. M., Tabaei, S. J. S., Taghipour, N., Koochaki, A., Hosseini, V., & Haghighi, A. N. (2023) · Iranian Journal of Parasitology · doi:10.18502/ijpa.v18i3.13762 · Cited by 2
“Recently, manipulating miRNA populations in different types of microorganisms and cells is possible, including enhancing the effect of miRNA on the target cell by using mimic miRNA or inhibiting its function by oligonucleotide analogs (13, 14).”
Background
Conserved Sequence Motif of RNA Aptamers Binding to the G-rich Sequence RNA
Cho, B. (2013) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2013.34.6.1924 · Cited by 2
Oligonucleotides containing a peptide internucleotide linkage. A novel class of modified oligonucleotides
Varizhuk, A. M., Kochetkova, S. V., Kolganova, N. A., Timofeev, E. N., & Florentiev, V. L. (2010) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162010040138 · Cited by 2
Established and Emerging Approaches for the Management of Dyslipidaemia
Norata, G. D. (2012) · Scientifica · doi:10.6064/2012/482423 · Cited by 2
Molecular biophysics underlying gene delivery
Zhao, X., Pan, F., Yaseen, M., & Lu, J. R. (2010) · Annual Reports Section C (Physical Chemistry) · doi:10.1039/b903512p · Cited by 2
Biotechnological Approaches for the Treatment of Inflammatory Diseases
Iansante, V., Capece, D., Murgo, S., Mancarelli, M. M., Zazzeroni, F., & Alesse, E. (2009) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/187152309787580793 · Cited by 2
“More than 50 clinical studies used antisense strategies spanning a variety of disease processes, including inflammation [104].”
Background
Versatile synthesis of amino acid functionalized nucleosides via a domino carboxamidation reaction
Gheerardijn, V., den Begin, J. V., & Madder, A. (2014) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.10.268 · Cited by 2
Bioanalysis of Therapeutic Oligonucleotides Using Hybridization-Based Immunoassay Techniques
Bonilla, J. V., & Srivatsa, G. S. (2011) · CRC Press eBooks · doi:10.1201/b10714-13 · Cited by 2
Diastereomer-Specific Repertoire of 7′R- or 7′S-Me-Carba-Locked Nucleic Acids (cLNAs) in Antisense Oligo/RNA Duplexes and Engineering of Physico-chemical and Enzymological Properties
Li, Q., Plashkevych, O., Upadhayaya, R. S., Deshpande, S. G., Földesi, A., & CHATTOPADHYAYA, J. B. (2014) · RNA technologies · doi:10.1007/978-3-642-54452-1_12 · Cited by 2
“Generally, there are several main types of anti-mRNA strategies, involving antisense approach (Crooke 2004), ribozymes, DNA enzymes (Schubert and Kurreck 2004; Santoro and Joyce 1997), RNA interference (Novina and Sharp 2004), micro-RNAs (miRNA) (Bartel 2004), or triple helix-forming oligonucleotides (TFOs) (Buchini a…”
Background
Properties of DNA-Capped Nanoparticles
Yang, W., Chen, Y., & Cheng, W. (2014) · Springer eBooks · doi:10.1007/978-3-642-31107-9_54 · Cited by 2
RNA Interference with siRNA.
Joyce, H., Bray, I. M., & CLYNES, M. M. (2006) · PubMed · Cited by 2
Telomerase inhibition, telomere attrition and proliferation arrest of cancer cells induced by phosphorothioate ASO-NLS conjugates targeting hTERC and siRNAs targeting hTERT
Diala, I., Shiohama, Y., Fujita, T., Kotake, Y., Demonacos, C., Krstic–Demonacos, M., Leva, G. D., & Fujii, M. (2020) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2020.1713357 · Cited by 2
“oligonucleotide assembled in 1 mol scale on CPG (PROLIGO, 500 Å, 30-40 mol/g) support was modified at the 5’-end of the oligonucleotides ([17]).”
Method
Bcl-2-targeted cancer therapeutics
Khorchid, A., & Beauparlant, P. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.6.805 · Cited by 2
“In phosphorothioated DNA, one of the non-bridging oxygen atoms in the phosphodiester linkage is substituted with sulfur [47,48].”
Background
Oligonucleotides and their Derivatives
Stetsenko, D. A. (2008) · doi:10.1002/9783527626175.ch19 · Cited by 2
Knockdown of Δ-5 Fatty Acid Desaturase Is More Than Just a Fad
Morrow, N. M., & Huff, M. W. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310382 · Cited by 2
Genetically Modified Stem Cells for Transplantation
Phillips, M. I. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-417-3_6 · Cited by 1
Efficient Suppression of Tissue Factor Synthesis Using Antisense Oligonucleotides Selected by an Enhanced Strategy for Evaluation of Structural Characteristics
Förster, Y., & Schwenzer, B. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0144 · Cited by 1
“The level of target protein is reduced by steric hindrance of translation or by activation of RNase H and degradation of target mRNA (Crooke, 2004a; Coppelli and Grandis, 2005; Chan et al., 2006).”
Drug discovery
Miller, S. M., Moos, W. H., Munk, B. H., & Munk, S. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-08-100625-2.00011-8 · Cited by 1
Introduction to Pharmacology of Macrophages with Drug Delivery Perspective
Gupta, M., Pathak, A., Pathak, Y. V., & Gupta, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-84164-5_1 · Cited by 1
The Current Status of Antisense Gene Therapies for Bacteria-caused Diseases Challenges and Opportunities
Ding, F., Li, J., Liang, X., Wang, F., & Wang, J. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230118152428 · Cited by 1
The art of healing hearts: Mastering advanced RNA therapeutic techniques to shape the evolution of cardiovascular medicine in biomedical science
Hou, G., Alissa, M., Alsuwat, M. A., Alarjany, H. M. A., Alzahrani, K. J., Althobaiti, F. M., Mujalli, H. M., Alotaiby, M. M., Al-Doaiss, A. A., & Anthony, S. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102627 · Cited by 1
Viral Vectors for RNA Interference Applications in Cancer Research and Therapy
Fechner, H., & Kurreck, J. (2011) · Wiley eBooks · doi:10.1002/9783527634057.ch44 · Cited by 1
Genesis and Biological Applications of Locked Nucleic Acids (LNAs)
Kaur, H., & Maiti, S. (2010) · doi:10.1002/9780470664001.ch8 · Cited by 1
Gene Therapy Strategies: Constructing an AAV Trojan Horse
Phillips, M. I., de Oliveira, E. M., Shen, L., Tang, Y., & Qian, K. (2010) · Genomics · doi:10.1002/9780470711675.ch12 · Cited by 1
Synthesis of oligo-2′-O-methylribonucleotides containing α-amino acid residues in 2′-position
Kazanova, E. V., Zubin, E. M., Kachalova, V. B., Stetsenko, D. A., Gait, M. J., & Oretskaya, T. S. (2007) · Russian Chemical Bulletin · doi:10.1007/s11172-007-0120-2 · Cited by 1
Inhibition of Dab2 Expression with Antisense Oligodeoxynucleotides in Mouse Embryos
Cheung, K., Mok, S. C., Zhao, H., Rezaie, P., & Chan, W. Y. (2008) · Neuroembryology and Aging · doi:10.1159/000173720 · Cited by 1
Locked Nucleic Acid Oligonucleotides toward Clinical Applications
Veedu, R. N., & Wengel, J. (2011) · doi:10.1002/9781118092804.ch9 · Cited by 1
“The first- and second-generation antisense oligonucleotides (AsONs) have been evolved to contain DNA phophorothioate nucleotides coupled with other chemical modifications such as 2′-O-Methyl-RNA (2′-OMe) and 2′-O-MethoxyethylRNA (2′-MOE) [30].”
Background
DNA ANALOGS FOR THE PURPOSE OF GENE THERAPY
Svahn, M. G. (2007) · Figshare · Cited by 1
Regulating Gene Expression through Engineered RNA Technologies
Win, M. N. (2009) · CRC Press eBooks · doi:10.1201/9781420077667.ch8 · Cited by 1
Insulin Resistance
Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2009) · Wiley eBooks · doi:10.1002/9780470747919.ch31 · Cited by 1
Antisense Oligonucleotides and siRNA as Specific Inhibitors of Gene Expression: Mechanisms of Action and Therapeutic Potential
Förster, Y., & Schwenzer, B. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-474-2_20 · Cited by 1
“In mice, rats, and monkeys, the elimination half-life is nearly 30 days in plasma and several tissues [2].”
BackgroundInfluential
Controlled Intracellular Localization of Oligonucleotides by Chemical Conjugation
Kubo, T., Bakalova, R., Zhelev, Z., Ohba, H., & Fujii, M. (2006) · Springer eBooks · doi:10.1007/4-431-27879-6_15 · Cited by 1
Midkine Is a Potential Therapeutic Target of Hepatocellular Carcinoma
Dai, L. C., Yao, X., & Zhong, J. (2012) · Springer eBooks · doi:10.1007/978-94-007-4234-5_24
Engineering Cell Function by RNA Interference
Gredell, J. A., Kini, H. K., & Walton, S. P. (2009) · Cell engineering · doi:10.1007/978-90-481-2245-5_9
“However, the relatively high concentrations of antisense oligonucleotides required to achieve the desired effect were often a challenge, in particular for in vivo applications, due to immunogenicity of natural and chemically-modified oligonucleotides ( Crooke, 2004 ).”
Background
Oligonucleotides in Sensing and Diagnostic Applications
Radecka, H., Radecki, J., Ghidini, A., Murtola, M., Strömberg, R., D’Urso, A., Petrovic, A. G., Fragalà, M. E., Tamargo, M. A., Ellestad, G. A., et al. (2015) · Wiley eBooks · doi:10.1002/9781118696880.ch3
Antisense DNA in Eukaryotes
Kurreck, J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-374984-0.00078-4
Studies Of Molecular Structure-Function Relationships For A Pyrrolysine-Containing Methyltransferase And Novel Rna-Cleaving Protein Nucleic Acids
Kang, T.-W. P. (2009) · OhioLink ETD Center (Ohio Library and Information Network)
Antisense Oligodeoxynucleotide Technology:A Novel Tool for Gene Silencing in Higher Plants
Dinç, E. (2012)
Antisenes-, Ribozym- und RNA-Interferenz-Strstegien: Methoden des posttranskriptionellen Gene Silencing in der Molekularen Medizin
Kurreck, J., Schubert, S., & Erdmann, V. A. (2008) · Springer eBooks · doi:10.1007/978-3-540-69414-4_18
Human dendritic cells and hepatitis C Virus
Landi, A. (2009) · University Library - University of Saskatchewan (University of Saskatchewan)
Engineering RNA-Based Circuits
Narayanaswamy, R., & Ellington, A. D. (2006) · Springer eBooks · doi:10.1007/3-540-27262-3_22 · Cited by 1
“Antisense-based therapies have been developed to selectively inhibit a variety of genes (Crooke 2004); one such molecule (Vitravene) has been commercialized as an antiviral agent.”
Background
alpha-Hydroxy-2-nitrobenzylphosphonat modifizierte Oligonucleotide : Synthese, Eigenschaften und neue Synthesekonzepte
Hohlfeld, A. (2005)
SELEX with Affinity Chromatography on RNA-RNA Interaction
Cho, B. (2015) · Journal of the Korean Chemical Society · doi:10.5012/jkcs.2015.59.1.93
Specifically Deoxyribozyme of the PTPRO Gene as a Potential Gene Therapy Means for Human Hepatocellular Carcinoma
Su, C. N., & Yu, M. (2013) · Advanced materials research · doi:10.4028/www.scientific.net/amr.781-784.1203
COMPARATIVE ANALYSIS OF DISEASE-ASSOCIATED MUTATIONS IN THE CODING REGIONS OF ALTERNATIVELY AND CONSTITUTIVELY SPLICED HUMAN GENES
Huang, Q., Li, Y., Li‐Ling, J., Huang, H., Chen, X., & MA, F. (2008) · Journal of Biological Systems · doi:10.1142/s0218339008002563
Role of sigma-1 receptors in capsaicin-induced mechanical hypersensitivity: studies with sigma-1 ligands, knockout mice and antisense oligodeoxynucleotides
Fernández, E., & Manuel, J. (2011) · Institutional Repository of the University of Granada (University of Granada)
Synthesis of Oligonucleotide Conjugates and Phosphorylated Nucleotide Analogues: An Improvement to a Solid Phase Synthetic Approach
Romanucci, V., Zarrelli, A., Napoli, L. D., Marino, C. D., & Fabio, G. D. (2013) · Journal of Chemistry · doi:10.1155/2013/469470
“, proteins and peptides, saccharides, fluorophores and photoprobes, inhibitors, and vitamins) that provide the conjugate with a desired novel property offers a feasible way to address these requirements [1–16].”
BACTERIAL GENE EXPRESSION INHIBITION WITH ANTISENSE PEPTIDE NUCLEIC ACIDS
Dryselius, R. (2005) · Figshare
Targeting Nucleic Acids in Bacteria with Synthetic Ligands
Nikravesh, A. (2008) · Figshare
New targets and developments in lipoproteins control
Norata, G. D. (2013) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s34904
“Following hybridization to the mRNA, the ASO inhibits translation and splicing and leads to degradation of the mRNA by ribonuclease (RNase).(3) ASO kinetics are characterized by a large and rapid distribution to the liver following parenteral administration, thus making”
Method
Entry of antisense oligonucleotides into Streptococcus mutans
McLeod, F. S. A. (2013) · Otago University Research Archive (University of Otago)
Properties of Nucleic Acid Amphiphiles and Their Biomedical Applications
Liu, H. (2015) · Springer eBooks · doi:10.1007/978-3-662-46226-3_7
“Synthetic nucleic acids, such as plasmid DNA, [1] siRNA, [2] antisense DNA, [3] molecular beacons, [4] aptamers [5], and DNAzymes [6], are powerful tools for dissecting, detecting, regulating, or inhibiting biological functions at molecular and cellular levels.”
Background
Amino-Functionalized Oligonucleotides with Peptide Internucleotide Linkages
Varizhuk, A. M., Kochetkova, S. V., Fedotov, A. U., Kolganova, N. A., Timofeev, E. N., & Florentiev, V. L. (2012) · Letters in Organic Chemistry · doi:10.2174/157017812800221799
“ON analogs are extensively used for manipulation of gene expression via antisense or RNA interference mechanisms [1-8].”
Background
der Fakultät für Chemie und Pharmazie der
München, L.-M.-U. (2008)
Polysaccharide/Polynucleotide Complexes for Cell-Specific DNA Delivery
Mochizuki, S., & Sakurai, K. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849737388-00190
Gene Suppression with Chitosan Nanoparticles
Akbuğa, J., Özbaş‐Turan, S., & Ekentok, C. (2016) · Springer eBooks · doi:10.1007/978-3-662-47862-2_23
Applications of nucleic acid aptamers in bioanalysis and targeted delivery
Bandhaya, A. (2012) · doi:10.25560/14458
Antisense Oligonucleotids and Antibacterial Use
Tekintaş, Y., Dora, D. D., & Limoncu, M. H. (2016) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.5222/tmcd.2016.051

Authors: Crooke, S. T.
Affiliations: Ionis Pharmaceuticals (United States) (US)
Corresponding author: Crooke, Stanley T.
ORCID: Crooke, Stanley T.
Venue: Annual Review of Medicine
Publisher: Annual Reviews
Published: 2004-02-01
Volume: 55
Issue: 1
Pages: 61-95
ISSN: 0066-4219 (ISSN-L)
1545-326X
DOI: 10.1146/annurev.med.55.091902.104408
OpenAlex: W2138668121
Cited by: 417
References: 243
Citations by year: 2026: 1 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 9 · 2018: 5 · 2017: 15 · 2016: 12 · 2015: 14 · 2014: 16 · 2013: 24 · 2012: 32
FWCI: 3.07
Type: journal article
Language: en
Open access: closed
Locations: Annual Review of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords: antisense technology, oligonucleotide analogues, RNA hybridization, RNA degradation, RNA splicing, antisense drug development, pharmacokinetics, toxicity, target validation
MeSH terms: Animals, Humans, Oligonucleotides, Antisense, Biomedical Technology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Progress in Antisense Technology

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks